Unknown

Dataset Information

0

Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine ?4?2 receptors: unique role of halogen bonding revealed.


ABSTRACT: The ?4?2 subtype of the nicotinic acetylcholine receptor has been pursued as a drug target for treatment of psychiatric and neurodegenerative disorders and smoking cessation aids for decades. Still, a thorough understanding of structure-function relationships of ?4?2 agonists is lacking. Using binding experiments, electrophysiology and x-ray crystallography we have investigated a consecutive series of five prototypical pyridine-containing agonists derived from 1-(pyridin-3-yl)-1,4-diazepane. A correlation between binding affinities at ?4?2 and the acetylcholine-binding protein from Lymnaea stagnalis (Ls-AChBP) confirms Ls-AChBP as structural surrogate for ?4?2 receptors. Crystal structures of five agonists with efficacies at ?4?2 from 21-76% were determined in complex with Ls-AChBP. No variation in closure of loop C is observed despite large efficacy variations. Instead, the efficacy of a compound appears tightly coupled to its ability to form a strong intersubunit bridge linking the primary and complementary binding interfaces. For the tested agonists, a specific halogen bond was observed to play a large role in establishing such strong intersubunit anchoring.

SUBMITTER: Rohde LA 

PROVIDER: S-EPMC3281707 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine α4β2 receptors: unique role of halogen bonding revealed.

Rohde Line Aagot Hede LA   Ahring Philip Kiær PK   Jensen Marianne Lerbech ML   Nielsen Elsebet Østergaard EØ   Peters Dan D   Helgstrand Charlotte C   Krintel Christian C   Harpsøe Kasper K   Gajhede Michael M   Kastrup Jette Sandholm JS   Balle Thomas T  

The Journal of biological chemistry 20111213 6


The α4β2 subtype of the nicotinic acetylcholine receptor has been pursued as a drug target for treatment of psychiatric and neurodegenerative disorders and smoking cessation aids for decades. Still, a thorough understanding of structure-function relationships of α4β2 agonists is lacking. Using binding experiments, electrophysiology and x-ray crystallography we have investigated a consecutive series of five prototypical pyridine-containing agonists derived from 1-(pyridin-3-yl)-1,4-diazepane. A c  ...[more]

Similar Datasets

| S-EPMC4118137 | biostudies-literature
| S-EPMC4732226 | biostudies-literature
| S-EPMC6004331 | biostudies-literature
| S-EPMC4155659 | biostudies-literature
| S-EPMC3200116 | biostudies-literature
| S-EPMC9204775 | biostudies-literature
| S-EPMC4398594 | biostudies-literature
| S-EPMC8469569 | biostudies-literature
| S-EPMC3096806 | biostudies-literature
| S-EPMC5626944 | biostudies-literature